Pharmaceutical Technology
Enveda is an AI-powered drug discovery platform company that reads nature's chemistry to identify new medicines approximately 4 times faster than industry standards. The company has achieved unicorn status following a $150M Series D funding round and is backed by major investors including Sanofi, Lux Capital, and Baillie Gifford. Enveda's first medicines are currently in clinical trials with a deep pipeline in development, including their lead asset ENV-294. The company is focused on reinventing drug discovery by combining artificial intelligence with natural product chemistry to accelerate the path from discovery to clinical development.
Industry
Pharmaceutical Technology
Company Size
201-500 employees
Remote Policy
Hybrid
Beta · Sourced from candidate reports
Be the first to share your experience with Enveda.
Your reply helps other candidates know what to expect.
